Clinical Trial Update: Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 clinical trial is evaluating a CBD/THC-containing product as a potential treatment for Alzheimer's disease, and the study is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CBD (cannabidiol) (cannabidiol)
• THC (tetrahydrocannabinol) (tetrahydrocannabinol)

Snippet

Sponsor: Federal University of Latin American Integration | Conditions: Alzheimer Disease (AD) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING